Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

radioimmunotherapy

  • MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy
    Open Access
    MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy
    Julie Constanzo, Aliasghar Parach, Timothee David, Joshua Karam, Frank Bruchertseifer, Alfred Morgenstern, Marta Jarlier, Manuel Bardiès, Emmanuel Deshayes, Amelie Gudin-de-Vallerin, Florence Boissière-Michot, Evelyne Lopez-Crapez and Jean-Pierre Pouget
    Journal of Nuclear Medicine May 1, 2025, 66 (5) 785-792; DOI: https://doi.org/10.2967/jnumed.124.268857
  • <sup>211</sup>At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation
    You have access
    211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation
    Sofia H.L. Frost, Johnnie J. Orozco, Tom A. Bäck, Brian W. Miller, Erlinda B. Santos, Aimee Kenoyer, Sue E. Knoblaugh, Donald K. Hamlin, D. Scott Wilbur and Brenda M. Sandmaier
    Journal of Nuclear Medicine September 1, 2024, 65 (9) 1443-1449; DOI: https://doi.org/10.2967/jnumed.124.267540
  • Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of <sup>225</sup>Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft Models
    You have access
    Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of 225Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft Models
    Christian W. Wichmann, Katherine A. Morgan, Zhipeng Cao, Laura D. Osellame, Nancy Guo, Hui Gan, Edward Reilly, Ingrid J.G. Burvenich, Graeme J. O’Keefe, Paul S. Donnelly and Andrew M. Scott
    Journal of Nuclear Medicine September 1, 2024, 65 (9) 1456-1462; DOI: https://doi.org/10.2967/jnumed.123.266894
  • Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer
    You have access
    Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer
    Kyeara N. Mack, Zachary V. Samuels, Lukas M. Carter, Tara D. Viray, Komal Mandleywala, Cory L. Brooks, Michael A. Hollingsworth, Prakash Radhakrishnan and Jason S. Lewis
    Journal of Nuclear Medicine April 1, 2024, 65 (4) 580-585; DOI: https://doi.org/10.2967/jnumed.123.266524
  • Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
    You have access
    Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
    Clara Diaz Garcia-Prada, Léna Carmes, Salima Atis, Ali Parach, Alejandro Bertolet, Marta Jarlier, Sophie Poty, Daniel Suarez Garcia, Wook-Geun Shin, Stanislas Du Manoir, Jan Schuemann, Olivier Tillement, François Lux, Julie Constanzo and Jean-Pierre Pouget
    Journal of Nuclear Medicine December 1, 2023, 64 (12) 1956-1964; DOI: https://doi.org/10.2967/jnumed.123.265418
  • Open Access
    Theranostics in Hematooncology
    Andreas K. Buck, Sebastian E. Serfling, Sabrina Kraus, Samuel Samnick, Niklas Dreher, Takahiro Higuchi, Leo Rasche, Hermann Einsele and Rudolf A. Werner
    Journal of Nuclear Medicine July 1, 2023, 64 (7) 1009-1016; DOI: https://doi.org/10.2967/jnumed.122.265199
  • Evaluation of Candidate Theranostics for <sup>227</sup>Th/<sup>89</sup>Zr Paired Radioimmunotherapy of Lymphoma
    Open Access
    Evaluation of Candidate Theranostics for 227Th/89Zr Paired Radioimmunotherapy of Lymphoma
    Diane S. Abou, Mark Longtine, Amanda Fears, Nadia Benabdallah, Ryan Unnerstall, Hannah Johnston, Kyuhwan Shim, Abbie Hasson, Hanwen Zhang, David Ulmert, Floriane Mangin, Serife Ozen, Laurent Raibaut, Stéphane Brandès, Michel Meyer, Jean-Claude Chambron, David S. Tatum, Darren Magda, Richard L. Wahl and Daniel L.J. Thorek
    Journal of Nuclear Medicine July 1, 2023, 64 (7) 1062-1068; DOI: https://doi.org/10.2967/jnumed.122.264979
  • Cure of Disseminated Human Lymphoma with [<sup>225</sup>Ac]Ac-Ofatumumab in a Preclinical Model
    Open Access
    Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model
    Mark S. Longtine, Kyuhwan Shim, Mark J. Hoegger, Nadia Benabdallah, Diane S. Abou, Daniel L.J. Thorek and Richard L. Wahl
    Journal of Nuclear Medicine June 1, 2023, 64 (6) 924-931; DOI: https://doi.org/10.2967/jnumed.122.265167
  • Radioimmunoscintigraphy and Pretreatment Dosimetry of <sup>131</sup>I-Omburtamab for Planning Treatment of Leptomeningeal Disease
    You have access
    Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal Disease
    Neeta Pandit-Taskar, Milan Grkovski, Pat B. Zanzonico, Keith S. Pentlow, Shakeel Modak, Kim Kramer and John L. Humm
    Journal of Nuclear Medicine June 1, 2023, 64 (6) 946-950; DOI: https://doi.org/10.2967/jnumed.122.265131
  • Cure of Disseminated Human Lymphoma with [<sup>177</sup>Lu]Lu-Ofatumumab in a Preclinical Model
    Open Access
    Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model
    Kyuhwan Shim, Mark S. Longtine, Diane S. Abou, Mark J. Hoegger, Richard S. Laforest, Daniel L.J. Thorek and Richard L. Wahl
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 542-548; DOI: https://doi.org/10.2967/jnumed.122.264816

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
SNMMI

© 2025 SNMMI

Powered by HighWire